Serum CXCL12 concentration in patients with severe traumatic brain injury are associated with mortality

Clinica Chimica Acta

Volumn 454, Issue , 2016, Pages 6-9

  Chen, Tie Jiang ^a   Wu, Wu Quan ^a   Ying, Guang Rong ^a   Fu, Qing Yang ^a   Xiong, Kai ^a  

^a YIWU CENTRAL HOSPITAL   (China)

Author keywords

CXC chemokine ligand 12; Mortality; Severity; Traumatic brain injury

Indexed keywords

BIOLOGICAL MARKER; STROMAL CELL DERIVED FACTOR 1; CXCL12 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; GLASGOW COMA SCALE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRAUMATIC BRAIN INJURY; ADOLESCENT; BLOOD; BRAIN INJURIES; INJURY SCALE; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRAIN INJURIES; CHEMOKINE CXCL12; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRAUMA SEVERITY INDICES; YOUNG ADULT;

EID: 84952776387     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.12.033     Document Type: Article

References (31)

1. Shi H.Y., Hwang S.L., Lee I.C., Chen I.T., Lee K.T., Lin C.L. Trends and outcome predictors after traumatic brain injury surgery: a nationwide population-based study in Taiwan. J. Neurosurg. 2014, 121:1323-1330.
2. Dong X.Q., Huang M., Yang S.B., Yu W.H., Zhang Z.Y. Copeptin is associated with mortality in patients with traumatic brain injury. J. Trauma 2011, 71:1194-1198.
3. Flaada J.T., Leibson C.L., Mandrekar J.N., Diehl N., Perkins P.K., Brown A.W., et al. Relative risk of mortality after traumatic brain injury: a population-based study of the role of age and injury severity. J. Neurotrauma 2007, 24:435-445.
4. Lippert-Gruner M., Maegele M., Haverkamp H., Klug N., Wedekind C. Health-related quality of life during the first year after severe brain trauma with and without polytrauma. Brain Inj. 2007, 21:451-455.
5. Zhang Z.Y., Zhang L.X., Dong X.Q., Yu W.H., Du Q., Yang D.B., et al. Comparison of the performances of copeptin and multiple biomarkers in long-term prognosis of severe traumatic brain injury. Peptides 2014, 60:13-17.
6. Wang K.Y., Yu G.F., Zhang Z.Y., Huang Q., Dong X.Q. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin. Chim. Acta 2012, 413:1737-1741.
7. Shen L.J., Yang S.B., Lv Q.W., Zhang G.H., Zhou J., Guo M., et al. High plasma adiponectin levels in patients with severe traumatic brain injury. Clin. Chim. Acta 2014, 427:37-41.
8. Ozyurt E., Goksu E., Cengiz M., Yilmaz M., Ramazanoglu A. Retrospective analysis of prognostic factors of severe traumatic brain injury in a university hospital in Turkey. Turk. Neurosurg. 2015, 25:877-882.
9. Andriessen T.M., Jacobs B., Vos P.E. Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J. Cell. Mol. Med. 2010, 14:2381-2392.
10. Plesnila N. The immune system in traumatic brain injury. Curr. Opin. Pharmacol. 2015, 26:110-117.
11. Kochanek P.M., Berger R.P., Bayir H., Wagner A.K., Jenkins L.W., Clark R.S. Biomarkers of primary and evolving damage in traumatic and ischemic brain injury: diagnosis, prognosis, probing mechanisms, and therapeutic decision making. Curr. Opin. Crit. Care 2008, 14:135-141.
12. Miñambres E., Ballesteros M.A., Mayorga M., Marin M.J., Muñoz P., Figols J., et al. Cerebral apoptosis in severe traumatic brain injury patients: an in vitro, in vivo, and postmortem study. J. Neurotrauma 2008, 25:581-591.
13. Lu J., Goh S.J., Tng P.Y., Deng Y.Y., Ling E.A., Moochhala S. Systemic inflammatory response following acute traumatic brain injury. Front. Biol.(Landmark Ed) 2009, 14:3795-3813.
14. Nonaka M. Evolution of the complement system. Subcell. Biochem. 2014, 80:31-43.
15. Merle N.S., Church S.E., Fremeaux-Bacchi V., Roumenina L.T. Complement system part I - molecular mechanisms of activation and regulation. Front. Immunol. 2015, 6:262.
16. Merle N.S., Noe R., Halbwachs-Mecarelli L., Fremeaux-Bacchi V., Roumenina L.T. Complement system part II: role in immunity. Front. Immunol. 2015, 6:257.
17. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
18. Li M., Ransohoff R.M. Multiple roles of chemokine CXCL12 in the central nervous system: a migration from immunology to neurobiology. Prog. Neurobiol. 2008, 84:116-131.
19. Itoh T., Satou T., Ishida H., et al. The relationship between SDF-1alpha/CXCR4 and neural stem cells appearing in damaged area after traumatic brain injury in rats. Neurol. Res. 2009, 31:90-102.
20. Schutt R.C., Burdick M.D., Strieter R.M., Mehrad B., Keeley E.C. Plasma CXCL12 levels as a predictor of future stroke. Stroke 2012, 43:3382-3386.
21. Duan X.X., Zhang G.P., Wang X.B., Yu H., Wu J.L., Liu K.Z., et al. The diagnostic and prognostic value of serum CXCL12 levels in patients with ischemic stroke. Neurol. Sci. 2015, 36:2227-2234.
22. Marshall L.F., Marshall S.B., Klauber M.R., Clark M.V. A new classification of head injury based on computerized tomography. J. Neurosurg. 1991, 75:S14-S20.
23. Wang Y., Huang J., Li Y., Yang G.Y. Roles of chemokine CXCL12 and its receptors in ischemic stroke. Curr. Drug Targets 2012, 13:166-172.
24. Petit I., Jin D., Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol. 2007, 28:299-307.
25. Shin J.H., Park Y.M., Kim D.H., Moon G.J., Bang O.Y., Ohn T., et al. Ischemic brain extract increases SDF-1 expression in astrocytes through the CXCR2/miR-223/miR-27b pathway. Biochim. Biophys. Acta 1839, 2014:826-836.
26. Khan M.Z., Brandimarti R., Shimizu S., Nicolai J., Crowe E., Meucci O. The chemokine CXCL12 promotes survival of postmitotic neurons by regulating Rb protein. Cell Death Differ. 2008, 15:1663-1672.
27. Mao W., Yi X., Qin J., Tian M., Jin G. CXCL12 inhibits cortical neuron apoptosis by increasing the ratio of Bcl-2/Bax after traumatic brain injury. Int. J. Neurosci. 2014, 124:281-290.
28. Kim Y.S., Baek W., Kim M.K., Kim H.Y., Lee K.Y., Lee Y.J., et al. Association between serum stromal cell-derived factor-1α and long-term outcome of acute ischemic stroke. Eur. Neurol. 2012, 67:363-369.
29. Wurster T., Stellos K., Geisler T., Seizer P., Andia M.E., Schuster A., et al. Expression of stromal-cell-derived factor-1 (SDF-1): a predictor of ischaemic stroke?. Eur. J. Neurol. 2012, 19:395-401.
30. Kwon H.S., Kim Y.S., Park H.H., Choi H., Lee K.Y., Lee Y.J., et al. Increased VEGF and decreased SDF-1α in patients with silent brain infarction are associated with better prognosis after first-ever acute lacunar stroke. J. Stroke Cerebrovasc. Dis. 2015, 24:704-710.
31. Navarro-Sobrino M., Rosell A., Hernández-Guillamon M., Penalba A., Boada C., Domingues-Montanari S., et al. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 2011, 216:205-211.